Fig. 1 · Structure

Documents & Downloads

Irsogladine

Cat. No. A10480 CAS 57381-26-7
Rsogladine is an anti-gastric ulcer agent that facilitates gap-junctional intercellular communication through M1 muscarininc acetylcholine receptor binding.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
AChR
mAChR
PDE

Irsogladine Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Irsogladine from 3 published references. In vitro models include Caco-2 cells. In vivo models include male C57BL/6-ApcMin/+ mice (Min mice).

Irsogladine In Vitro Studies

In 2D-hiPSC-SI treated with Irsogladine before ASA addition, LY permeability in the ASA + Irso group was significantly lower than in the ASA 400 µg/mL group. In the PDE4B1 assay, Irsogladine inhibited PDE activity by 20 and 31 % at 50 and 100 μM, respectively. In Caco-2 cells treated with Irsogladine at 200 μM for 24 h, AP-1 and NF-κB transcriptional activities decreased by 47% and 38% of the untreated control value, respectively. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Irsogladine with ASA reduces LY permeability

Cell-based study · 2D-hiPSC-SI; n = 3 [1]

In 2D-hiPSC-SI, Irsogladine at 16 µg/mL was applied to the basal side for 24 h before ASA addition. LY permeability in the ASA + Irso group was significantly lower than in the ASA 400 µg/mL group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LY permeabilityReported result LY permeability of the ASA + Irso group was significantly lower than that of the ASA 400 µg/mL group (p < 0.01)[1]

Literature-Reported Treatment Conditions

Treatment concentration
16 µg/mL
Exposure duration
incubating for 24 h before ASA addition; Samples were collected 24 h after ASA addition.
Method
to the basal side of 2D-hiPSC-SI
Vehicle
basal medium
Co-treatment
Other interventions in this design: ASA 400 µg/mL. Compound effect isolated by the comparison: LY permeability of the ASA + Irso group was significantly lower than that of the ASA 400 µg/mL group.
Methods and source locations

Compound reported in the paper: Irsogladine; Compound label in the paper: Irsogladine Irsogladine

Evidence for Irsogladine as the maleate form reported in the paper, not the free base/neutral form supplied as A10480; no salt equivalence, dose conversion or lot validation.

2. Materials and Methods > 2.3. Evaluation of the Effect of Irsogladine on ASA-Induced Small Intestinal Injury (S15, S16); 3. Results > 3.5. Irsogladine Plays a Protective Role against ASA-Induced Injury in 2D-hiPSC-SI (S90, S91); Figure 4 legend (S126); Figure 5 legend (S130, S132, S137)

LY permeability: LY permeability; comparator: ASA 400 µg/mL group — Figure 5 legend (S137)

Irsogladine inhibits PDE activity

Cell-based study · 10U PDE 4B1 (BPS Biosciences) [2]

In the PDE4B1 assay, Irsogladine was tested at 50 and 100 μM with DMSO as the vehicle control. PDE activity was inhibited by 20 and 31 %, respectively.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of PDE4B1PDE 4B1 inhibition 20 and 31 %[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 and 100 μM
Exposure duration
for 20 min. After incubation, the cAMP substrate (final concentration 1.25 µM) was added and incubated for 1 h.
Method
incubated with reference and tested compound
Vehicle
dimethyl sulfoxide (DMSO)
Methods and source locations

Compound reported in the paper: Irsogladine; Compound label in the paper: Irsogladine Irsogladine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Protocols for in vitro experiments > The phosphodiesterase 4B1 (PDE 4B1) activity assay (S110, S112, S113, S115, S116, S117); Results > The phosphodiesterase 4B1 (PDE 4B1) assay (S252); Table 2 legend (S289)

Inhibition of PDE4B1: Inhibition of PDE4B1; comparator: DMSO as vehicle control — Materials and methods > Protocols for in vitro experiments > The phosphodiesterase 4B1 (PDE 4B1) activity assay (S110); Results > The phosphodiesterase 4B1 (PDE 4B1) assay (S252)

Irsogladine decreases transcriptional activities in Caco-2 cells

Cell-based study · Caco-2 cells [3]

Caco-2 cells were treated with Irsogladine at 200 μM for 24 h. AP-1 and NF-κB transcriptional activities decreased by 47% and 38% of the untreated control value, respectively.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AP-1 transcriptional activityAP-1 transcriptional activity 47%[3]

Literature-Reported Treatment Conditions

Treatment concentration
200 μM
Exposure duration
24 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Irsogladine; Compound label in the paper: Irsogladine Irsogladine

Evidence for Irsogladine as the maleate form reported in the paper, not the free base/neutral form supplied as A10480; no salt equivalence, dose conversion or lot validation.

RESULTS > The effects of six gastric mucosal protectants on AP-1, NF-κB, NRF2, p53 and STAT3 transcriptional activity in Caco-2 cells (S1, S2); Figure 2 legend (S117, S119)

AP-1 transcriptional activity: AP-1 transcriptional activity; comparator: without the test reagent — RESULTS > The effects of six gastric mucosal protectants on AP-1, NF-κB, NRF2, p53 and STAT3 transcriptional activity in Caco-2 cells (S2); Figure 2 legend (S119)

Irsogladine In Vivo Studies

Male C57BL/6-ApcMin/+ mice received Irsogladine at 5 and 50 ppm in powdered basal diet for 8 weeks. Total polyp counts decreased to 69.3% and 66.1% of the untreated control value, respectively. [3]

Irsogladine reduces polyp counts in Min mice

Animal study · Male C57BL/6-ApcMin/+ mice (Min mice) [3]

Male C57BL/6-ApcMin/+ mice received Irsogladine at 5 and 50 ppm in powdered basal diet for 8 weeks. Total polyp counts decreased to 69.3% and 66.1% of the untreated control value, respectively.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
total number of polypstotal number of polyps 69.3% and 66.1% of the untreated control value, respectively[3]

Conditions shared by the study groups

Route
mixed at concentrations of 5 and 50 ppm in an AIN-76A powdered basal diet
Treatment course
for 8 weeks
Vehicle
AIN-76A powdered basal diet
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Irsogladine 5 and 50 ppmbasal dietThe total number of polyps decreased with the administration of 5 and 50 ppm irsogladine maleate to 69.3% and 66.1% of the untreated control value, respectively.[3]
Irsogladine 5 and 50 ppm
Model: Male C57BL/6-ApcMin/+ mice (Min mice)
Methods and source locations

Compound reported in the paper: Irsogladine; Compound label in the paper: Irsogladine Irsogladine

Evidence for Irsogladine as the maleate form reported in the paper, not the free base/neutral form supplied as A10480; no salt equivalence, dose conversion or lot validation.

RESULTS > The suppression of intestinal polyp formation in Min mice by irsogladine maleate (S23, S26); MATERIALS AND METHODS > Animals (S57, S59); MATERIALS AND METHODS > Animal experiment protocols (S62)

total number of polyps: total number of polyps; comparator: basal diet — RESULTS > The suppression of intestinal polyp formation in Min mice by irsogladine maleate (S26)

Irsogladine 5 and 50 ppm · RESULTS > The suppression of intestinal polyp formation in Min mice by irsogladine maleate (S26); MATERIALS AND METHODS > Animals (S59); MATERIALS AND METHODS > Animal experiment protocols (S62)

Specifications

Manufacturer Adooq Bioscience
CAS Number 57381-26-7
Formula C9H7Cl2N5
Molecular Weight 256.09
SMILES
C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 2 mg/mL (7.8 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Irsogladine Research References

  1. [1] Kanno T, Katano T, Ogawa I, et al. Protective Effect of Irsogladine against Aspirin-Induced Mucosal Injury in Human Induced Pluripotent Stem Cell-Derived Small Intestine. Medicina (Kaunas) (2022). PMID: 36676718 DOI: 10.3390/medicina59010092 Source material
  2. [2] Mogilski S, Kubacka M, Łażewska D, et al. Aryl-1,3,5-triazine ligands of histamine H4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide. Inflamm Res (2017). PMID: 27766379 DOI: 10.1007/s00011-016-0997-z Source material
  3. [3] Onuma W, Tomono S, Miyamoto S, et al. Irsogladine maleate, a gastric mucosal protectant, suppresses intestinal polyp development in Apc-mutant mice. Oncotarget (2016). PMID: 26840084 DOI: 10.18632/oncotarget.7082 Source material

Added to your cart

View Cart Checkout
Loading...